

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
December 18, 2019

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Lauren Tesh Hotaki, PharmD, BCPS, BCIDP

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Massimo Cristofanilli, MD, FACP

Associate Director of Translational Research and
Precision Medicine
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois

Susan Halabi, PhD

Professor of Biostatistics and Bioinformatics
Duke University Medical Center
Durham, North Carolina

Christian S. Hinrichs, MD

Investigator & Lasker Clinical Research Scholar
Experimental Transplantation and Immunology
Branch
National Cancer Institute
National Institutes of Health (NIH)
Bethesda, Maryland

Philip Hoffman, MD

(Chairperson)
Professor of Medicine
The University of Chicago
Section of Hematology/Oncology
Department of Medicine
Chicago, Illinois

Heidi D. Klepin, MD, MS

Associate Professor of Internal Medicine
Section of Hematology and Oncology
Wake Forest University Health Sciences
Winston Salem, North Carolina

Anthony D. Sung, MD

Assistant Professor of Medicine
Duke University School of Medicine
Duke Adult Blood and Marrow Transplant Clinic
Durham, North Carolina

Thomas S. Uldrick, MD, MS

Deputy Head, Global Oncology
Associate Member, Vaccine and Infectious Disease
Division
Associate Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
December 18, 2019

DRAFT MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Jonathan D. Cheng, MD

(Industry Representative)

Vice President and Oncology Therapeutic Area
Head Merck Research Laboratories, Oncology
Clinical Research
North Wales, Pennsylvania

TEMPORARY MEMBERS (Voting)

Randy W. Hawkins, MD

(Acting Consumer Representative)

Department of Internal Medicine
Internal Medicine/Pulmonary & Critical Care
Charles R. Drew University of Medicine and
Science
Los Angeles, California

Christian F. Meyer, MD, MS, PhD

Clinical Associate and Assistant Professor of Adult
Sarcomas, Medical Oncology
Johns Hopkins Hospital
Baltimore, Maryland

Richard F. Riedel, MD

Associate Professor of Medicine (with Tenure)
Associate Director, Duke Sarcoma Program
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

William D. Tap, MD

Associate Professor of Medicine
Weill Cornell Medical College
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Kimberly A. Webb, MA

(Patient Representative)

Huntington Beach, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
December 18, 2019

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE),
FDA
Acting Director, Office of Oncologic Disease
(OOD)
Office of New Drugs (OND), CDER, FDA

Steven Lemery, MD

Acting Director
Division of Oncology 3 (DO3)
OOD, OND, CDER, FDA

Leslie Doros, MD

Clinical Reviewer
Melanoma/Sarcoma Team
DO3, OOD, OND, CDER, FDA

Marc Theoret, MD

Acting Deputy Director
OOD, OND, CDER, FDA
Acting Associate Director for Immunotherapeutics
OCE, FDA

Ashley Ward, MD

Clinical Team Leader
Melanoma/Sarcoma Team
DO3, OOD, OND, CDER, FDA